Sign up to receive CIDP information, updates, and content that matter to you!
*indicates required field
Which of these options best describes you?*
I authorize argenx US, Inc. ("argenx"), its affiliates, and companies working with argenx to use my contact information and health information (“Information”) to contact me by direct mail, email, telephone, and autodialed text message for marketing purposes, such as to provide me with information, offers, and promotions regarding chronic inflammatory demyelinating polyneuropathy, argenx products and programs, to conduct market research or surveys, and to use my Information to develop future products, services, and programs.
I understand that I may withdraw my authorization provided above by emailing privacyUS@argenx.com or following the unsubscribe instructions on the communication. Unless I withdraw this authorization, it will remain effective for 2 years. Copies of this authorization may be obtained by emailing privacyUS@argenx.com.
Check your inbox for updates and information about CIDP.
Read CIDP community stories
Intended for U.S. audiences only.
US-NON-23-00053 V1 05/2023
You are now leaving this website.